Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Leqvio (inclisiran by Year
Leqvio (inclisiran — 2 times/year injectable siRNA for lowering LDL-C cholesterol) ($M)
Novartis Leqvio (inclisiran: $1,198M in FY2025, up 58.9% from a year earlier.
Latest, FY2025
1,198
Period ended Dec 31, 2025
Change on a year earlier
+58.9%
754 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Leqvio | 1 198 | 754 | 59 | 57”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Leqvio (inclisiran — 2 times/year injectable siRNA for lowering LDL-C cholesterol) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,198 | +58.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 754 | +112.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 355 | +217.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 112 | +833.3% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 12 | – | Novartis Form 6-K (0001370368-23-000008) ↗ |
Breakdown
What makes up leqvio (inclisiran
Cite this data
StockData. (2026). Novartis Leqvio (inclisiran ($M), annual FY2021–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.